Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction

Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction

Abstract Aims Murine models implicate phosphodiesterase 9A (PDE9A) as a nitric oxide‐independent regulator of cyclic guanosine monophosphate and promising novel therapeutic target in heart failure (HF) with preserved ejection fraction (HFpEF). This study describes PDE9A expression in endomyocardial...

Full description

Bibliographic Details
Main Authors: Christian Besler, Karl‐Philipp Rommel, Karl‐Patrik Kresoja, Justus Mörbitz, Holger Kirsten, Markus Scholz, Karin Klingel, Joachim Thiery, Ralph Burkhardt, Petra Büttner, Volker Adams, Holger Thiele, Philipp Lurz
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:ESC Heart Failure
Subjects:
Phosphodiesterase 9A
Heart failure
Heart failure with preserved ejection fraction
Fibrosis
Inflammation
Online Access:https://doi.org/10.1002/ehf2.13327

Internet

https://doi.org/10.1002/ehf2.13327

Similar Items